MEDNET 2007 - 12th World Congress on Internet in Medicine

MEDNET is a scientific conference organized under the auspices of the Society for the Internet in Medicine (SIM). MEDNET 2007 will be hosted by the Center for Healthcare Management at Germany's No. 1 listed Business School Leipzig Graduate School of Management (HHL).

The official journal is the Journal of Medical Internet Research (JMIR), the leading Open Acesss eHealth journal - www.jmir.org.

Besides the focus points "Economics of Internet & Medicine Applications" and "EHR and the electronic Health Card" MEDNET 2007 will have - as every year - many topics around Internet & Medicine.

MEDNET 2007 Tracks and Themes:

  • Putting electronic health records online
  • Open Source Initiatives in Internet & Healthcare
  • Integrated care & Workflow Management over the Internet
  • Patient Education and Information
  • Etrials: using the web and etechnologies for clinical trials
  • Public (e-)health, population health technologies, surveillance
  • Telemedicice and Heart Failure Management
  • Internet-based Management of Pace-Makers
  • Legal aspects of Internet and Medicine
  • Web-based medical education
  • Health communication on the internet
  • Online pharmacies
  • Internet publishing in medicine
  • Other topics

For further information, please visit:
www.mednet2007.com

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...